INSULET CORP 8-K

What Happened

• Insulet Corporation announced on June 25, 2026 (8-K filed) that its Board appointed Jonathan J. Mazelsky as a Class II director, effective July 1, 2026. Mr. Mazelsky will stand for election by stockholders at Insulet’s 2027 Annual Meeting of Stockholders. A press release announcing the appointment was furnished as Exhibit 99.1.

Key Details

• Appointment effective date: July 1, 2026; will stand for election at 2027 Annual Meeting.
• Compensation: an initial grant of restricted stock units with a grant date fair value of $216,548 (pro‑rated from a $260,000 annual award) plus cash board fees under Insulet’s non‑employee director compensation program.
• Background: Executive Chair of IDEXX Laboratories since May 2026; CEO of IDEXX Oct 2019–May 2026 (and Interim CEO Jun–Oct 2019); prior senior roles at Philips Healthcare (2001–2012) and Agilent Technologies, and earlier experience at Hewlett‑Packard. He currently serves on the board of Dentsply Sirona Inc.
• No arrangements or understandings with other persons regarding his selection and no reportable related‑party transactions under Item 404 of Regulation S‑K.

Why It Matters

• Governance: The addition of Mr. Mazelsky changes Insulet’s board composition and brings an executive with extensive medical device/animal health and healthcare technology experience, which may be relevant to Insulet’s strategy and oversight.
• Financial impact: The filing discloses only routine director compensation (RSU grant and cash board fees); no other financial commitments or related‑party transactions were reported.
• Next steps: Mr. Mazelsky will be subject to shareholder election at the 2027 annual meeting, and investors can refer to Insulet’s April 6, 2026 proxy statement for details on non‑employee director pay.